Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)333: A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J Am Coll Cardiol. 2001;37(8): doi: /S (01) Frequency of device use in the SCA&I Registry. Figure Legend:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)333: A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J Am Coll Cardiol. 2001;37(8): doi: /S (01) Balloon stent versus balloon angioplasty in coronary artery disease. Cumulative frequency distribution curves for the two study groups, showing minimum lumen diameters measured before and after intervention and follow-up (B), the percentage of stenosis at follow-up, and the percentage of patients with clinical end points. Significant differences were apparent that consistently favored the stent group over the angioplasty group with respect to the increased minimal lumen diameter at intervention (A) and follow-up (B), the percentage of stenosis at follow-up (C), and the incidence of major clinical events (D). The vertical dashed line in D indicated the end of the study. Reproduced with permission from Serruys PW, et al. N Engl J Med 1994;331:489–95 (32). Figure Legend:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)333: A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J Am Coll Cardiol. 2001;37(8): doi: /S (01) Mortality at the end of study in all the trials comparing primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic drug treatment. The rates for each study are grouped by thrombolytic drug regimen. The odds ratio with 95% confidence intervals (CIs) are plotted on the right. Tests for homogenity: streptokinase trials, p = 0.08; tissue-type plasminogen activator (t-PA) trials, p = 0.33; accelerated t-PA trials, p = 0.21; thrombolytic regiment, p = 0.96; and overall; p = Percentages are pooled results and odds ratios calculated by exact method using all trials. CI = confidence interval; PTCA = percutaneous transluminal coronary angioplasty. Reproduced with permission from Weaver WD, et al. JAMA 1997;278:2093–8 (272). Reference numbers within the figure correspond to the original article. Figure Legend:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)333: A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J Am Coll Cardiol. 2001;37(8): doi: /S (01) Death or nonfatal myocardial infarction outcomes at 30 days in 10 randomized, placebo-controlled trials of GP IIb/IIIa blockers. CI = confidence interval; GP = glycoprotein; MI = myocardial infarction; OR = odds ratio. Reproduced with permission from Topol EJ, et al. Lancet 1999;353:227–31 (497). Data and acronyms from references 30–39 (These numbers coincide with references in the original article). Risk ratio with 95% CI, size of RR box being proportional to total sample size. Frequency of death or nonfatal myocardial infarction in columns 4 and 5. Overall (all 10 trials) benefit of GP IIb/IIIa blockade highly significant (RR = 0.79 [95% CI 0.73–0.85]; p < 10 −9 ). Figure Legend:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)333: A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J Am Coll Cardiol. 2001;37(8): doi: /S (01) AHA guide to comprehensive risk reduction for patients with coronary and other vascular disease. ACE = angiotensin-converting enzyme; AHA = American Heart Association; CHF = congestive heart failure; HDL =, high density lipoprotein; LDL = low density lipoprotein; LV = left ventricular; MI = myocardial infarction; TG = triglycerides. Adapted with permission from Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Circulation 1995;92:2–4. June 1999 Update. Figure Legend: